This study will consist of four cohorts (Cohort 1, Cohort 2, Cohort 3, and Cohort 4).~Participants will be assigned to each of the cohorts as per Child-Pugh classification:~Cohort 1: Mild hepatic impairment (Child-Pugh A), cotadutide 50 μg~Cohort 2: Moderate hepatic impairment (Child-Pugh B), cotadutide 50 μg~Cohort 3: Severe hepatic impairment (Child-Pugh C), cotadutide 50 μg~Cohort 4: Normal hepatic function, cotadutide 50 μg
This study will assess the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous injection of cotadutide in participants with mild, moderate or severe hepatic impairment compared to participants with normal hepatic function.